

24. Kobayashi M, Bennett NM, Gierke R, Almandares O, Moore MR, Whitney CG, et al. Intervals between PCV13 and PPSV23 vaccines. *MMWR Morb Mortal Wkly Rep* 2015; 64(34): 944–947.
25. Robert Koch Institut. Empfehlungen der Ständigen Impfkommision beim Robert Koch-Institut 2020/2021. *Epidemiologisches Bulletin* 2020; 34. 20. August 2020.
26. El-Solh AA, Sikka P, Ramadan F, et al. Etiology of severe pneumonia in the very elderly. *Am J Respir Crit Care Med* 2001; 163(3): 645–651.
27. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. *Clin Infect Dis* 2004; 39(11): 1642–1650.
28. Fry AM, Shay DK, Holman RC, et al. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988–2002. *JAMA* 2005; 294(21): 2712–2719.
29. Kothe H, Bauer T, Marre R, et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. *Eur Respir J* 2008; 32(1): 1391–1346.
30. Isturiz RE, Ramirez J, Self WH, et al. Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. *Vaccine* 2019; 37: 3352–3361.
31. Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults. *Vaccine* 2013; 31(35): 3577–3584.
32. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60–64 years of age. *Vaccine* 2014; 32(20): 2364–2374.
33. Shiramoto M, Hanada R, Juergens C, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. *Hum Vaccines Immunother* 2015; 11(9): 2198–2206.
34. van Deursen AMM, van Houten MA, Webber C, et al. Immunogenicity of the 13-valent pneumococcal conjugate vaccine in older adults with and without comorbidities in the community-acquired pneumonia immunization trial in adults (CAPiTA). *Clin Infect Dis Off Publ Infect Dis Soc Am* 2017; 65(5): 787–795.
35. Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against Pneumococcal pneumonia in adults. *N Engl J Med* 2015; 372: 1114–1125.
36. Jefferson T, Di Pietrantonio C, Al-Ansary LA, et al. Vaccines for preventing influenza in the elderly. *Cochrane Database Syst Rev* 2010(2):CD004876.
37. Súhrn charakteristických vlastností lieku Prevenar 13. Dostupné na https://www.ema.europa.eu/en/documents/product-information/prevenar-13-epar-product-information_sk.pdf, (SPC Prevenar).
38. WHO. Guidance on routine immunization services during COVID-19 pandemic in the WHO European Region..
39. Ministerstvo zdravotnictva České republiky. Klinická skupina COVID MZ. Doporučení KS COVID MZ k provádění očkování v průběhu pandemie onemocnění COVID-19. Dátum vydania: 10.4. 2020. KS-COVID_ockovani_behem_pandemie(10042020) (MZ ČR 2020).
40. Root-Bernstein R. Age and Location in Severity of COVID-19 Pathology: Do Lactoferrin and Pneumococcal Vaccination Explain Low Infant Mortality and Regional Differences? *BioEssays* 2020. DOI: 10.1002/bies.202000076.
41. Dražan D. Pneumokokové vakcíny. *Klin Farmakol Farm* 2010; 24(1): 15–18.
42. Cucchiari D, Pericàs JM, Riera J, et al. Pneumococcal superinfection in COVID-19 patients: A series of 5 cases. *Med Clin (Barc)* 2020; <https://doi.org/10.1016/j.medcli.2020.05.022>
43. Hendaus MA, Jomha FA. Covid-19 induced superimposed bacterial infection. *J Biomolecul Struct Dynamics* 2020; <https://doi.org/10.1080/07391102.2020.1772110>.
44. Root-Bernstein R. Possible Cross-Reactivity between SARS-CoV-2 Proteins, CRM197 and Proteins in Pneumococcal Vaccines May Protect Against Symptomatic SARS-CoV-2 Disease and Death. *Vaccines* 2020;8:559. doi:10.3390/vaccines8040559.
45. Sultana J, Mazzaglia G, Luxi N, et al. Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations. *Expert Rev vaccines* 2020. <https://doi.org/10.1080/14760584.2020.1825951>.